Issued on behalf of Premaitha Health plc
Manchester, UK: Friday, 11 March 2016
Premaitha Health plc
(“Premaitha” or the “Company”)
Premaitha wins at North West Business Masters Awards 2016
Manchester, UK – 11 March 2016: Premaitha Health plc (AIM: NIPT), the company enabling wide scale adoption of a safe, fast, accurate and complete CE Marked non-invasive prenatal screening system, was the winner of the prestigious ‘Judges Special Recognition Award’ at the North West Business Masters Awards 2016. The awards, held last night in Manchester, celebrate excellence in all aspect of business life.
Premaitha, based in Manchester Science Park, uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women. The Company’s IONA® test was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions. Unlike existing prenatal screening methods, due to its speed and high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures which carry a risk of miscarriage.
Dr Stephen Little, CEO of Premaitha, commented:
“Premaitha is delighted to be recognised by the North West Business Masters Awards for our innovation in developing safer and more accurate screening tests for pregnant women. Premaitha is a proudly Manchester-based company at the forefront of genetics and an emerging multi-billion pound market for non-invasive prenatal testing.”
For more information, please contact:
Premaitha Health plc
Joanne Cross, Head of Marketing
Tel: +44 (0) 161 667 6865
investors@premaitha.com
Vigo Communications
Ben Simons / Fiona Henson
Tel: +44 (0) 20 7830 9700
premaitha@vigocomms.com
About Premaitha:
Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.
Premaitha’s lead test – the IONA® test – was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions. The IONA® test is performed on the mother’s blood sample – which contains traces of fetal DNA – and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its speed and high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures which carry a risk of miscarriage.
NIPT is an emerging, multi-billion dollar global market and Premaitha’s complete CE Marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening solution in-house.
Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.
